Rat and bat hunt helps heal old rift
In the British Solomon Islands Protectorate in 1927, a warrior named Basiana led the Kwaio resistance against colonial rule of the island of Malaita, in which 15 people -including an Australian and a Britonwere killed with spears and a few rifles. The London Colonial Office asked Australia to quell the 'uprising' . In the months that followed, Australians and Solomon Islanders killed at least 60 Kwaio, desecrating shrines and violating cultural taboos. Eventually, Basiana surrendered and was hanged with six conspirators. For almost a century, these events
Heat and soil vie for waste
The Renewable Heat Incentive scheme in the United Kingdom has led some industries to turn much of their organic waste into feedstocks for energy production. Previously, this material -such as biosolids from water processing -was used to replenish soil carbon. This switch might inadvertently undermine the global initiative to increase soil carbon to mitigate climate change, which was ratified in 2015.
This potential conflict needs to be part of the policy discourse and research agenda for energy and the environment. Reductions in organic carbon hamper soil functions, such as water-holding capacity, and reduce crop productivity. But knowledge gaps remain about the necessary level, composition and quality of carbon required to maintain and improve soil health and fertility.
The products of anaerobic digestion of organic wastes for heat production are widely used as soil conditioners. But they have a lower ratio of carbon to nitrogen than do conventional composted vegetation and food waste. It is not known just how low the ratio of such wastes can go before it becomes worthless to return them to the soil. 
Reproducibility in public and private
The reproducibility crisis in biomedical science seems to have alarmed industry more than the academic community (see C. G. Begley and L. M. Ellis Nature 483, 531-533; 2012). In our view, this is because they have different yardsticks for success in research.
Despite the advent of important new therapeutics, the number of innovative treatments reaching the patient is disappointingly low. To help rectify this, industry is investing in drug-discovery alliances with peers and academic groups, and in precision medicine. It sees high standards of research quality as the route to the most promising drug candidates and to maximum return on investment.
By contrast, academic scientists may be reluctant to devote extra time and effort to confirming research results in case they fail. That would put paid to publication in highimpact journals, damage career opportunities and curtail further funding. Evidence of questionable practices such as selective publishing and cherry-picking of data indicates that rigour is not always a high priority.
Paradoxically 
